-
1
-
2
New Tendencies in the Development of the EU Competition Law – the AstraZeneca case
Published 2011-10-01Get full text
Article -
3
Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
Published 2021-01-01“…A 26-year-old Iraqi male laboratory analyst with an unremarkable medical history presented with severe thrombocytopenia 2 days after receiving the Oxford-AstraZeneca coronavirus disease-2019 vaccine. The patient was asymptomatic with unremarkable examination findings. …”
Get full text
Article -
4
COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
Published 2025-01-01Subjects: Get full text
Article -
5
Extensive Longitudinal Transverse Myelitis Temporally Related to the Use of AZD1222, AstraZeneca COVID-19 Vaccine: Cerebrospinal Fluid Analysis and Recent Data Review
Published 2022-01-01“…We present a case of extensive longitudinal transverse myelitis after vaccination with AZD1222, AstraZeneca COVID-19 vaccine, which was the first case reported in Brazil. …”
Get full text
Article -
6
A descriptive-multivariate analysis of community knowledge, confidence, and trust in COVID-19 clinical trials amongst Ugandans working in healthcare settings.
Published 2021Subjects: “…COVID-19 clinical trials in resource poor countries; COVID-19 vaccines; Clinical trials in Africa; COVID-19 and medical workers; vaccines, Oxford-AstraZeneca.…”
Get full text
Article -
7
-
8
-
9
NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome
Published 2025-01-01Get full text
Article -
10
-
11
-
12
-
13
The Christmas Season as a Risk Factor for Chronic Obstructive Pulmonary Disease Exacerbations
Published 2010-01-01Get full text
Article -
14
-
15
-
16
-
17
-
18
Adjustable Maintenance Dosing with Budesonide/Formoterol Reduces Asthma Exacerbations Compared with Traditional Fixed Dosing: A Five-Month Multicentre Canadian Study
Published 2003-01-01“…BACKGROUND: Adjustable maintenance dosing with budesonide/formoterol in a single inhaler (Symbicort, AstraZeneca, Lund, Sweden) may provide a convenient means of maintaining asthma control with the minimum effective medication level.…”
Get full text
Article -
19
Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies
Published 2012-01-01“…To investigate the link between phospholipogenic administration and incidence of preclinical histological signals, an internal AstraZeneca in vivo toxicology report database was searched to identify phospholipogenic and nonphospholipogenic compounds. …”
Get full text
Article -
20